FDA again rejects tabelecleucel for EBV-driven post-transplant lymphoproliferative disease

The FDA has issued a second complete response letter to Atara Biotherapeutics for its biologics license application of tabelecleucel for adults and children with Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
The company had submitted the application for Ebvallo (tabelecleucel) — an off-the-shelf allogeneic Epstein-Barr virus-specific cytotoxic T-cell therapy — as monotherapy for affected adult and pediatric patients aged 2 years and older who had received at least one prior therapy, including an anti-CD20 containing regimen.
The FDA wrote that it is unable to approve





